NOVITA SUL TRATTAMENTO DEL CARCINOMA MAMMARIO: MALATTIA TRIPLO NEGATIVA
|
|
- Austin Moore
- 5 years ago
- Views:
Transcription
1 SUPERNOVAE IN ONCOLOGIA NOVITA SUL TRATTAMENTO DEL CARCINOMA MAMMARIO: MALATTIA TRIPLO NEGATIVA Dr. Matteo Lambertini U.O. Oncologia Medica 2 IRCCS AOU San Martino IST, Genova Pisa, 14 novembre 2015
2 AGENDA Introduction Neoadjuvant therapy Adjuvant therapy Therapy for metastatic disease Future perspectives
3 AGENDA Introduction Neoadjuvant therapy Adjuvant therapy Therapy for metastatic disease Future perspectives
4 Triple-Negative Breast Cancer (TNBC) TNBC lacks expression of ER (<1%), PgR (<1%) and HER2 TNBC comprises approximately 15% of incident breast cancers Each year in the US alone out of 235,000 new cases 35,000 are TNBC Vast majority are candidates for adjuvant or neoadjuvant therapy Responsible for high degree of brest cancer mortality Coates AS et al, Ann Oncol 2015; 26: Brewster AM et al, Lancet Oncol 2014; 15:e
5 Triple-Negative Breast Cancer (TNBC) TNBC is associated with African American ethnicity, younger age, frequently interval tumors, advanced stage at diagnosis and poorer outcome when compared with other BC subtypes. Possible etiologic heterogeneity: protective effect of breastfeeding. BRCA mutations in nearly 20% of TNBC patients (vs 5% in non- TNBC): 16% BRCA1 & 4% BRCA2. TNBC is characterised by high cell proliferation, poor cellular differentiation, many recurrent copy number imbalances, and mutations in the TP53. Brewster AM et al, Lancet Oncol 2014; 15:e Islami F et al, Ann Oncol 2015 [Epub ahead of print]
6 Triple-Negative Breast Cancer (TNBC) Oakman C et al, The Breast 2010; 19:312-21
7 AGENDA Introduction Neoadjuvant therapy Adjuvant therapy Therapy for metastatic disease Future perspectives
8 pcr and TNBC Cortazar P et al, Lancet 2014; 384:164-72
9 pcr and TNBC Cortazar P et al, Lancet 2014; 384:164-72
10 Breast-Conserving Surgery and TNBC Slide 14 BCS successful: 94% BCS successful: 91% Golsham M et al, Ann Surg 2015; 262:434-9
11 Breast-Conserving Surgery and TNBC Golsham M et al, Ann Surg 2015; 262:434-9
12 Surgery Platinum Salts and NACT in TNBC GeparSixto (GBG 66) phase II study N=595 centrally confirmed TNBC or R HER2-positive breast cancer PM PMCb Non-pegylated liposomal Paclitaxel 80 mg/m² q1w doxorubicin 20 mg/m² q1w Carboplatin AUC 1.5* q1w Her2-pos: Trastuzumab 6(8) mg/kg q3w (for 1 year) + Lapatinib 750 mg/d 18 wks TNBC: Bevacizumab 15 mg/kg q3w *reduced from AUC 2 at amendment 1 after enrolment of 330 patients Von Minckwitz G et al, Lancet Oncol 2014; 15:747-56
13 Platinum Salts and NACT in TNBC Von Minckwitz G et al, Lancet Oncol 2014; 15:747-56
14 Platinum Salts and NACT in TNBC 315 patients (53.6%) Von Minckwitz G et al, Lancet Oncol 2014; 15:747-56
15 Platinum Salts and NACT in TNBC Von Minckwitz G et al, Lancet Oncol 2014; 15:747-56
16 Platinum Salts and NACT in TNBC Von Minckwitz G et al, ASCO Annual Meeting 2015
17 Platinum Salts and NACT in TNBC CALGB (Alliance) phase II study Clinical Stage II-III TNBC (n=443) Primary endpoint: pathologic complete response (pcr) breast and breast + axilla Sikov WM et al, J Clin Oncol 2015; 33:13-21
18 Platinum Salts and NACT in TNBC CALGB (Alliance) phase II study pcr breast=ypt0/is pcr breast/axilla=ypt0/is N0 Sikov WM et al, J Clin Oncol 2015; 33:13-21
19 Platinum Salts and NACT in TNBC Rates of pcr (ypt0 pn0) with NACT with carboplatin in TNBC Study No. Patients Standard CT Standard CT + carboplatin GeparSixto wp+lipo doxo CALGB wp ddac % 53% % 54% 15% absolute difference Von Minckwitz G et al, Lancet Oncol 2014; 15: Sikov WM et al, J Clin Oncol 2015; 33:13-21
20 Nab-Paclitaxel and NACT in TNBC Out of 1204 patients enrolled, 275 (22.8%) had TNBC Untch M et al, San Antonio Breast Cancer Symposium 2014
21 Nab-Paclitaxel and NACT in TNBC Untch M et al, San Antonio Breast Cancer Symposium 2014
22 Nab-Paclitaxel and NACT in TNBC Untch M et al, San Antonio Breast Cancer Symposium 2014
23 AGENDA Introduction Neoadjuvant therapy Adjuvant therapy Therapy for metastatic disease Future perspectives
24 Benefit of Adjuvant CT in TNBC Prospective cohort study NCCN database (4,113 patients): T1a,b N0 tumors treated between 2000 and 2009 Distant Relapse-Free Survival In TNBC (n=168 patients): 5-year DRFS pt1a: 93% 5-year DRFS pt1b: 90% In TNBC (n=195 patients): 5-year DRFS pt1a: 100% 5-year DRFS pt1b: 96% Vaz-Luis I et al, J Clin Oncol 2014; 32:
25 Adjuvant CT in TNBC Coates AS et al, Ann Oncol 2015; 26:
26 Impact of Adjuvant CT in TNBC British Columbia Cancer Agency stage I-III BC (7,178 patients): a total of 1,132 (15.8%) patients with ER neg and HER2 neg BC Cohort 1: Cohort 2: Cossetti RJD et al, J Clin Oncol 2015; 33:65-73
27 Adjuvant Taxanes in TNBC E1199 Phase III Study 1:1:1:1 AC x 4 P x 4 Q3 w Invasive breast carcinoma (N= 4,950 pts) - Radical surgery; - N pos or high risk N neg; - No distant metastasis. AC x 4 wp x 12 AC x 4 D x 4 Q3 w AC x 4 wd x 12 P vs D wt vs Q3T Primary endpoint: disease-free survival (DFS) Sparano JA et al, N Engl J Med 2008; 358: Sparano JA et al, J Clin Oncol 2015; 33:65-73
28 Adjuvant Taxanes in TNBC E1199 Phase III Study: 1,025 patients with TNBC p=0.010 p=0.019 Sparano JA et al, N Engl J Med 2008; 358: Sparano JA et al, J Clin Oncol 2015; 33:65-73
29 Adjuvant DD Chemotherapy in TNBC GIM2 Phase III Study Invasive breast carcinoma (N= 2,091 pts) - Radical surgery; - 1 pos nodes; - No supraclavicolar nodes; - No IBC, no stage IV. 1:1:1:1 EC x 4 T x 4 Q3 w FEC x 4 T x 4 Q3 w EC x 4 T x 4 Q2 w FEC x 4 T x 4 Q2 w EC vs FEC Q2 vs Q3 Primary endpoint: disease-free survival (DFS) Del Mastro L et al, Lancet 2015; 385:
30 Adjuvant DD Chemotherapy in TNBC GIM2 Phase III Study DFS OS EC vs FEC Q2 vs Q3 Del Mastro L et al, Lancet 2015; 385:
31 Adjuvant DD Chemotherapy in TNBC GIM2 Phase III Study: 335 patients with HR negative BC Disease-free survival: Q2 (dose-dense) vs Q3 (standard duration) Del Mastro L et al, Lancet 2015; 385:
32 Adjuvant DD Chemotherapy in TNBC SWOG S0221 Phase III Study 1:1:1:1 AC Q2 x 6 P Q2 x 6 Invasive breast carcinoma (N= 2,716 pts) - Radical surgery; - N pos or high risk N neg; - No distant metastasis. wac x 15 P Q2 x 6 AC Q2 x 6 wp x 12 wac x 15 wp x 12 DD AC vs wac DD P vs wp Primary endpoint: disease-free survival (DFS) Budd GT et al, J Clin Oncol 2015; 33:58-64
33 Adjuvant DD Chemotherapy in TNBC SWOG S0221 Phase III Study: 680 patients with TNBC Disease-free survival Budd GT et al, J Clin Oncol 2015; 33:58-64
34 LINEE GUIDA AIOM 2015
35 Adjuvant Ixabepilone in TNBC TITAN Phase III Study 609 patients Yardley DA et al, ASCO Annual Meeting 2015
36 Adjuvant Ixabepilone in TNBC TITAN Phase III Study Disease-Free Survival Overall Survival Yardley DA et al, ASCO Annual Meeting 2015
37 Adjuvant Bevacizumab in TNBC BEATRICE Phase III Study Cameron D et al, Lancet Oncol 2013; 14:933-42
38 Adjuvant Bevacizumab in TNBC BEATRICE Phase III Study Disease-Free Survival Overall Survival Cameron D et al, Lancet Oncol 2013; 14:933-42
39 Maintenance Adjuvant CT in TNBC IBCSG Phase III Study C: 50 mg/day continuously M: 2.5 mg twice/day 1,2 week 75% TNBC Colleoni M et al, ASCO Annual Meeting 2015
40 Maintenance Adjuvant CT in TNBC IBCSG Phase III Study Colleoni M et al, ASCO Annual Meeting 2015
41 Maintenance Adjuvant CT in TNBC IBCSG Phase III Study Colleoni M et al, ASCO Annual Meeting 2015
42 AGENDA Introduction Neoadjuvant therapy Adjuvant therapy Therapy for metastatic disease Future perspectives
43 Lines of Treatment in TNBC Dana-Farber Cancer Institute experience: 199 patients between 2004 and 2007, 44 with TNBC Number of lines of chemotherapy Overall survival Seah DSE et al, J Natl Compr Canc Netw 2014; 12:71-80
44
45 1 st Line Therapy: Platinum Salts CBCSG006 Trial Metastatic TNBC breast cancer (N=236pts) - Chinese patients - No prior therapy for advanced disease - ER and PR 10% and HER2 negative - Prior adjuvant taxanes allowed (> 6 months before study entry) 1:1 Cisplatin (75 mg/m 2 g1 q 21) + Gemcitabine (1250mg/m 2 g1,8 q 21) Paclitaxel (175 mg/m 2 g1 q 21) + Gemcitabine (1250mg/m 2 g1,8 q 21) Primary endpoints: progression-free survival (PFS) 1. To test non-inferiority of cisplatin plus gemcitabine compared with paclitaxel plus gemcitabine 2. If achieved, to test superiority of cisplatin plus gemcitabine compared with paclitaxel plus gemcitabine Hu XC et al, Lancet Oncol 2015; 16:436-46
46 1 st Line Therapy: Platinum Salts CBCSG006 Trial Progression-Free Survival Cisplatin: 7.73 months (95% CI, ) Paclitaxel: 6.47 months (95% CI, ) Hu XC et al, Lancet Oncol 2015; 16:436-46
47 1 st Line Therapy: Platinum Salts TNT Trial: CRUK/07/012 Tutt A et al, San Antonio Breast Cancer Symposium 2014
48 1 st Line Therapy: Platinum Salts TNT Trial: CRUK/07/012 Objective Response Rate Progression-Free Survival Overall Survival Tutt A et al, San Antonio Breast Cancer Symposium 2014
49 1 st Line Therapy: Platinum Salts TNT Trial: CRUK/07/012 Tutt A et al, San Antonio Breast Cancer Symposium 2014
50 1 st Line Therapy: Platinum Salts TNT Trial: CRUK/07/012 Tutt A et al, San Antonio Breast Cancer Symposium 2014
51 1 st and 2 nd Line Therapy: Platinum Salts TBCRC009 Trial High Homologous Recombination and mutations: BRCA mutant vs BRCA wild type High Homologous Recombination and responses: Responders vs Non responders Isakoff SJ et al, J Clin Oncol 2015; 33:1902-9
52
53
54 2 nd Line Therapy: Eribulin NCT Phase III Study Metastatic breast cancer (N= 1,102 pts) - Prior anthracycline- and taxane-based therapy - 3 lines of therapy ( 2 lines of therapy for advanced disease) - No anti-her2 agents if HER2 positive 1:1 Eribulin 1.4 mg/m 2 g1,8 q 21 Capecitabine 1,250 mg/m 2 BID g1-14 q 21 Primary endpoints: progression-free survival (PFS) and overall survival (OS) Kaufman PA et al, J Clin Oncol 2015; 33:
55 2 nd Line Therapy: Eribulin NCT Phase III Study Overall Survival Progression-Free Survival Overall Survival Subgroup Analysis Kaufman PA et al, J Clin Oncol 2015; 33:
56 AGENDA Introduction Neoadjuvant therapy Adjuvant therapy Therapy for metastatic disease Future perspectives
57 Future perspectives The Heterogeneity of TNBC BRCA and PARP-I Endocrine therapy Immunotherapy
58 Future perspectives The Heterogeneity of TNBC BRCA and PARP-I Endocrine therapy Immunotherapy
59 The Heterogeneity of TNBC Subtype Gene expression profile Clinical Basal-like 1 high Ki-67; DNA damage response BRCA-associated Basal-like 2 GF pathways Higher pcr Immunomodulatory Immune genes Mesenchymal Cell motility Lower DDFS Mesenchymal stem-like Cell motility; claudin-low Luminal androgen receptor Steroid pathways Apocrine features, higher LRF; PI3Kmut Lehman BD et al, J Clin Invest 2011; 121:
60 The Heterogeneity of TNBC Subtype Gene Ontology IHC analysis Hysto type Possible sensitivity Basal-like 1 Basal-like 2 Immunomodulatory Cell cycle and cell division DNA damage response Growth gactor signaling (EGFR, MET) High Ki67 -- Cisplatin PARP-Inhibitors -- Medullary Anti-EGFR Immune cell processes Immunotherapy? Mesenchymal-like Cell motility and cell differentation (TGF-β, Src); GF patways Mesenchymal Stem-like Luminal AR Angiogenesis Low levels prolif genes Claudin-low Hormonally regulated pathways -- Metaplastic PI3K-mTOR Inh (BEZ235) Src-Inhibitors (Dasatinib) -- Anti-angio AR + Molecular Apocrine AR antagonist Courtesy of M. De Laurentiis
61 Future perspectives The Heterogeneity of TNBC BRCA and PARP-I Endocrine therapy Immunotherapy
62 BRCA and PARP-I Iniparib in Unselected TNBC Overall Survival Overall Survival O Shaughnessy J et al, N Engl J Med 2011; 364: O Shaughnessy J et al, J Clin Oncol 2014; 32.
63 BRCA and PARP-I The Proof-of-Concept Trial: Olaparib in BRCA1 and BRCA2 mutant BC (54% were TNBC) Tutt A et al, Lancet 2010; 376:
64 BRCA and PARP-I Ongoing phase II and III studies Livraghi L et al, BMC Med 2015; 13:188
65 Future perspectives The Heterogeneity of TNBC BRCA and PARP-I Endocrine therapy Immunotherapy
66 Endocrine Therapy Androgen Receptor in TNBC Present in 10-30% (1-10% cut off) Better survival Expressed in older patients, lower grade tumors (G1-G2), higher PD-L1 expression Rare co-expression in patients with BRCA-mutation Gasparini P et al, PLOS One 2014; 9:e Loibl S et al, Breast Cancer Res Treat 2011; 130: Proverbs-Singh T et al, Endocr Rel Cancer 2015; 22:R87-R106. Tung N et al, ASCO Annual Meeting 2015 (abstract 1005)
67 Endocrine Therapy TBCRC 011 phase II study 12% IHC: AR > 10% CBR = 19% (95% CI, 7% - 39%) PFS = 12 weeks (95% CI, 11-22) Bicalutamide 150 mg daily Gucalp A et al, Cancer Res 2013; 19:
68 Metastatic breast cancer (N= 118 pts) - AR + ( 1% positive cells) advanced TNBC - Any number of prior therapies - No brain metastasis - Sufficient tissue available for biomarker discovery Endocrine Therapy MDV phase II study Enzalutamide 160 mg/day Stage 1 3 of 26 Evaluable have CBR16 Go to Stage 2 Stage 2 9 of 62 Evaluable have CBR16 Rejection of H 0 Cortes J et al, ESMO-ECCO Annual Meeting 2015
69 Overall Survival (%) Endocrine Therapy MDV phase II study ITT Population PREDICT AR+ mos 75.6 weeks (95% CI: 51.6, 91.4) PREDICT AR mos 32.3 weeks (95% CI: 20.7, 48.3) Weeks PREDICT AR+ mos 18.0 months PREDICT AR mos 7.5 months Cortes J et al, ESMO-ECCO Annual Meeting 2015
70 Endocrine Therapy Ongoing studies in breast cancer Proverbs-Singh T et al, Endocr Rel Cancer 2015; 22:R87-R106
71 Future perspectives The Heterogeneity of TNBC BRCA and PARP-I Endocrine therapy Immunotherapy
72 Immunotherapy Tumor Infiltrating Lymphocites (TIL): prognostic role in early stage TNBC and in patients with residual disease after neoadjuvant chemotherapy predictors of pcr after neaodjuvant chemotherapy (mainly in TNBC and HER2+) PD-L1 expression: The role of Immunity in TNBC Approximately 20-60% of TNBC Associated with: TIL, increased immune response genes and activation of immune pathways, AR+, no LVI Anti-PD-1 and anti-pd-l1 Abs break the immune tolerance at the tumor site leading to a lasting clinical benefit Adams S et al, J Clin Oncol 2014; 32: Dieci MV et al, Ann Oncol 2014; 25: Denkert C et al, J Clin Oncol 2015; 33: Dieci MV et al, Ann Oncol 2015; 26: Salgado R et al, Ann Oncol 2015; 26: Sabatier R et al, Oncotarget 2015; 6: Tung N et al, ASCO Annual Meeting 2015 (abstract 1005)
73 Immunotherapy Phase Ib study of pembrolizumab (anti-pd-1) in TNBC Recurrent or metastatic ER /PR /HER2 breast cancer ECOG PS 0-1 PD-L1 + tumor a No systemic steroid therapy No autoimmune disease (active or history of) No active brain metastases Pembro 10 mg/kg Q2W Complete Response Partial Response or Stable Disease Confirmed Progressive Disease b Discontinuation Permitted Treat for 24 months or until progression or intolerable toxicity Discontinue Patients Evaluable for Response a n = 27 Overall response rate 5 (18.5%) Best overall response Complete response b 1 (3.7%) Partial response b 4 (14.8%) Stable disease 7 (25.9%) Progressive disease 12 (44.4%) No assessment c 3 (11.1%) Nanda R et al, San Antonio Breast Cancer Symposium 2014
74 Immunotherapy Phase Ia study of MPDL3280A (atezolimumab, anti-pd-l1) Efficacy evaluable population with TNBC treated with MPDL3280A q 3 weeks: n=21 patients PD-L1+ at IHC (2/3) ORR=19% (2 CR and 2 PR) Median duration of response not reached: weeks PFS at 24 weeks: 27% Emens AL et al, AACR Annual Meeting 2015
75 Immunotherapy Ongoing studies in breast cancer TRIAL DRUG TARGET SETTING PANACEA Pembrolizumab PD-1 Metastatic HER2+ BC MK-3475 for Metastatic Inflammatory Breast Cancer (MIBC) PLX3397 and Pembrolizumab in Advanced Melanoma and Other Solid Tumors MK /KEYNOTE-012 in triple-negative breast cancer and head and neck cancer Safety study of nivolumab with Nab-Paclitaxel plus or minus Gemcitabine in Pancreatic Cancer, nabpaclitaxel/carboplatin in stage IIIB/IV Non-Small Cell Lung Cancer or nab-paclitaxel in recurrent metastatic breast cancer Pembrolizumab PD-1 Metastatic inflammatory BC Pembrolizumab PD-1 Metastatic TNBC Pembrolizumab PD-1 Metastatic TNBC Nivolumab PD-1 Recurrent Metastatic BC PDR001 in Patients With Advanced Malignancies PDR001 PD-1 Metastatic TNBC RADVAX Pembrolizumab + hypofractionated RT PD-1 Metastatic BC TONIC study (nivolumab after induction therapy for triple-negative breast cancer) Nivolumab PD-1 Metastatic TNBC JAVELIN Avelumab PD-L1 Metastatic BC IMpassion130 (in combination with nab-paclitaxel) Atezolimumab PD-L1 Untreated metastatic TNBC From: ClinicalTrials.gov. Courtesy of C. Solinas
76 Conclusions TNBC is heterogeneous Chemotherapy is mainstay and (at the moment) in unselected TNBC is the same as for other subtype Neoadjuvant: platinum salts and nab-paclitaxel? Adjuvant: dose-dense chemotherapy Metastatic setting: 1 st line: taxanes (+/- bevacizumab) platinum salts 2 nd line: eribulin platinum salts BRCA associated TNBC may be different: PARP-I and platinum salts to be considered. In all settings? Personalized therapy approaches: near future?
77
Triple Negative Breast Cancer: Part 2 A Medical Update
Triple Negative Breast Cancer: Part 2 A Medical Update April 29, 2015 Tiffany A. Traina, MD Breast Medicine Service Memorial Sloan Kettering Cancer Center Weill Cornell Medical College Overview What is
More informationLa malattia triplo negativa metastatica: quali trattamenti nella pratica clinica?
2018 CARCINOMA MAMMARIO: I TRAGUARDI RAGGIUNTI E LE NUOVE SFIDE La malattia triplo negativa metastatica: quali trattamenti nella pratica clinica? Roma, 27 Ottobre 2018 Relatore: Francesca Poggio Disclosure
More informationTriple Negative Breast cancer New treatment options arenowhere?
Triple Negative Breast cancer New treatment options arenowhere? Ofer Rotem, M.D., B.Sc. Breast Unit, Davidoff center Rabin Medical center October 2017 Case 6/2013 - M.D., 38 years old woman, healthy, no
More informationRole of chemotherapy in BRCA and Triple negative breast cancer. Fernando Moreno Servicio de Oncología Médica Hospital Clinico San Carlos
Role of chemotherapy in BRCA and Triple negative breast cancer Fernando Moreno Servicio de Oncología Médica Hospital Clinico San Carlos Association between TNBC & germline mutations in BRCA 1/2 TNBC is
More informationTriple negative breast cancer -neoadjuvant and adjuvant systemic therapy
Triple negative breast cancer -neoadjuvant and adjuvant systemic therapy Sung-Bae Kim, MD, PhD Department of Oncology Asan Medical Center University of Ulsan College of Medicine Seoul, Korea DISCLOSURE
More informationENFERMEDAD AVANZADA Qué hacemos con el triple negativo? Nuevas aproximaciones
ENFERMEDAD AVANZADA Qué hacemos con el triple negativo? Nuevas aproximaciones Javier Cortes, Hospital Universitario Ramon y Cajal, Madrid Vall d Hebron Institute of Oncology (VHIO), Barcelona Triple Negative
More informationManagement of Triple Negative Breast Cancer. Giuseppe Curigliano MD, PhD University of Milano and European Institute of Oncology
Management of Triple Negative Breast Cancer Giuseppe Curigliano MD, PhD University of Milano and European Institute of Oncology Outline Heterogeneity of TNBC Targeting TNBC by subtypes New antibody drug
More informationAlternativas terapéuticas en fenotipo triple negativo Javier Cortes, Hospital Universitario Ramon y Cajal, Madrid
Alternativas terapéuticas en fenotipo triple negativo Javier Cortes, Hospital Universitario Ramon y Cajal, Madrid Vall d Hebron Institute of Oncology (VHIO), Barcelona Triple Negative Breast Cancer Immunohistochemistry
More informationSubtype-directed therapy of TNBC Global Breast Cancer Conference 2015 & 4th International Breast Cancer Symposium Jeju Island, Korea, April 2015
Subtype-directed therapy of TNBC Global Breast Cancer Conference 2015 & 4th International Breast Cancer Symposium Jeju Island, Korea, April 2015 Ruth M. O Regan, MD Visiting Professor and Division Chief
More informationSystemic therapy of triple negative advanced breast cancer. Giuseppe Curigliano MD, PhD Breast Cancer Program Division of Early Drug Development
Systemic therapy of triple negative advanced breast cancer Giuseppe Curigliano MD, PhD Breast Cancer Program Division of Early Drug Development Outline State of the Art in the management of TN advanced
More informationImmunotherapy for Breast Cancer. Aurelio B. Castrellon Medical Oncology Memorial Healthcare System
Immunotherapy for Breast Cancer Aurelio B. Castrellon Medical Oncology Memorial Healthcare System Conflicts Research support : Cascadian therapeutics, Puma biotechnology, Odonate therapeutics, Pfizer,
More informationTNBC: What s new Déjà vu All Over Again? Lucy R. Langer, MD MSHS Compass Oncology - SABCS 2016 Review February 21, 2017
TNBC: What s new Déjà vu All Over Again? Lucy R. Langer, MD MSHS Compass Oncology - SABCS 2016 Review February 21, 2017 The problem with TNBC 1. Generally more aggressive 2. ONLY chemotherapy 3. No other
More informationAdvances in Breast Cancer Therapeutics in the Adjuvant and Metastatic Settings. Eve Rodler, MD University of California at Davis October 2016
Advances in Breast Cancer Therapeutics in the Adjuvant and Metastatic Settings Eve Rodler, MD University of California at Davis October 2016 17th Annual Advances in Oncology September 30-October 1, 2016
More informationTriple Negative Breast Cancer. Eric P. Winer, MD Dana-Farber Cancer Institute Harvard Medical School Boston, MA October, 2008
Triple Negative Breast Cancer Eric P. Winer, MD Dana-Farber Cancer Institute Harvard Medical School Boston, MA October, 2008 Triple Negative Breast Cancer 15% 25% Triple Negative 20% HER2+ ER+ Low Grade
More informationTriple-Negative Breast Cancer
June 2017 Triple-Negative Breast Cancer Amir Sonnenblick, MD, PhD Sharett institute of oncology Hadassah-Hebrew university medical center, Jerusalem, Israel This presentation is the intellectual property
More informationTreatment of Triple Negative Breast Cancer. Giuseppe Curigliano MD, PhD University of Milano and European Institute of Oncology
Treatment of Triple Negative Breast Cancer Giuseppe Curigliano MD, PhD University of Milano and European Institute of Oncology Outline Neoadjuvant treatment in triple negative EBC Picking optimal adjuvant
More information10/15/2012. Inflammatory Breast Cancer vs. LABC: Different Biology yet Subtypes Exist
Triple-Negative Breast Cancer: Optimizing Treatment for Locally Advanced Breast Cancer Beth Overmoyer MD Director, Inflammatory Breast Cancer Program Dana Farber Cancer Institute Overview Inflammatory
More informationTerapia sistemica neoadiuvante: in quali tumori? Quali risultati? Dott. Giacomo Pelizzari
Terapia sistemica neoadiuvante: in quali tumori? Quali risultati? Dott. Giacomo Pelizzari Neoadjuvant Treatment A window of opportunity Rational: Historically proposed to enable breast-conserving surgery
More informationSYSTEMIC TREATMENT OF TRIPLE NEGATIVE BREAST CANCER
SYSTEMIC TREATMENT OF TRIPLE NEGATIVE BREAST CANCER Sunil Shrestha 1*, Ji Yuan Yang, Li Shuang and Deepika Dhakal Clinical School of Medicine, Yangtze University, Jingzhou, Hubei Province, PR. China Department
More informationESMO Preceptorship Breast Cancer. Giuseppe Curigliano MD, PhD Breast Cancer Program Division of Early Drug Development Istituto Europeo di Oncologia
ESMO Preceptorship Breast Cancer Giuseppe Curigliano MD, PhD Breast Cancer Program Division of Early Drug Development Istituto Europeo di Oncologia Outline Rational for immune-based therapy in BC How to
More informationLocally Advanced Breast Cancer: Systemic and Local Therapy
Locally Advanced Breast Cancer: Systemic and Local Therapy Joseph A. Sparano, MD Professor of Medicine & Women s Health Albert Einstein College of Medicine Associate Chairman, Department of Oncology Montefiore
More informationImmunotherapy for Breast Cancer Clinical Development
Immunotherapy for Breast Cancer Clinical Development Laurence Buisseret, MD, PhD Breast Cancer Translational Research Laboratory Institut Jules Bordet Université Libre de Bruxelles (ULB) ESMO preceptorship
More information非臨床試験 臨床の立場から 京都大学医学部附属病院戸井雅和
資料 2 2 非臨床試験 臨床の立場から 京都大学医学部附属病院戸井雅和 1 Preclinical studies Therapeutic Window: Efficacy/Toxicity Disease Specificity Subtype Specificity Combination: Concurrent/Sequential Therapeutic situation: Response/
More informationBreast : ASCO Abstracts for Review
Breast : ASCO 2011 Susana Campos, MD, MPH Dana Farber Cancer Institute Abstracts for Review Prevention Neoadjuvant Metastatic Brain mets LBA 504: Exemestane for primary prevention of breast cancer in postmenopausal
More informationTriple-Negative Breast Cancer Time to Slice and Dice? Carsten Denkert, MD Charité University Hospital Berlin, Germany
Triple-Negative Breast Cancer Time to Slice and Dice? Carsten Denkert, MD Charité University Hospital Berlin, Germany Triple-Negative Breast Cancer (TNBC) 2018 Presentation Outline The molecular heterogeneity
More informationContemporary Chemotherapy-Based Strategies for First-Line Metastatic Breast Cancer
Contemporary Chemotherapy-Based Strategies for First-Line Metastatic Breast Cancer Hope S. Rugo, MD Professor of Medicine Director, Breast Oncology and Clinical Trials Education University of California
More informationClinical Research on PARP Inhibitors and Triple-Negative Breast Cancer (TNBC)
Clinical Research on PARP Inhibitors and Triple-Negative Breast Cancer (TNBC) Eric P Winer, MD Disclosures for Eric P Winer, MD No real or apparent conflicts of interest to disclose Key Topics: PARP and
More informationTriple negative breast cancer 2014 GASCO Annual meeting September 5 th 2014, Atlanta, GA
Triple negative breast cancer 2014 GASCO Annual meeting September 5 th 2014, Atlanta, GA Ruth M. O Regan, MD Professor and Vice-Chair for Educational Affairs, Department of Hematology and Medical Oncology,
More informationMetastatic NSCLC: Expanding Role of Immunotherapy. Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian
Metastatic NSCLC: Expanding Role of Immunotherapy Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian Disclosures: No relevant disclosures Please note that some of the studies reported in
More informationSystemic Therapy for Locally Advanced Breast Cancer
Systemic Therapy for Locally Advanced Breast Cancer Soo-Chin Lee Head & Senior Consultant Department of Haematology-Oncology National University Cancer Institute, Singapore Clinical Care Senior Principal
More informationBreast cancer treatment
Report from the San Antonio Breast Cancer Symposium Breast cancer treatment Determining the best options for select patient groups Sara Soldera, MD, Resident; Nathaniel Bouganim, MD, FRCPC, Medical Oncologist;
More informationOverview of nab-paclitaxel in Breast Cancer
Overview of nab-paclitaxel in Breast Cancer William J. Gradishar MD FASCO FACP Betsy Bramsen Professor of Breast Oncology Robert H. Lurie Comprehensive Cancer Center Northwestern University Feinberg School
More informationRecent Update in Management of Breast Cancer: Medical Oncology. Jin Hee Ahn, M.D., PhD. 23-April-2015
2015 GBCC & 4 th IBCS 1/37 Recent Update in Management of Breast Cancer: Medical Oncology Jin Hee Ahn, M.D., PhD. 23-April-2015 Department of Oncology, Asan Medical Center, UUCM, Seoul, Korea 2/37 3/37
More informationConsiderations in Adjuvant Chemotherapy. Joyce O Shaughnessy, MD Baylor Sammons Cancer Center Texas Oncology US Oncology
Considerations in Adjuvant Chemotherapy Joyce O Shaughnessy, MD Baylor Sammons Cancer Center Texas Oncology US Oncology 80 70 60 50 40 30 20 10 0 EBCTCG 2005/6 Overview Control Arms with No Systemic Treatment
More informationWhat to do after pcr in different subtypes?
What to do after pcr in different subtypes? Luca Moscetti Breast Unit Università degli Studi di Modena e Reggio Emilia Policlinico di Modena, Italy Aims of neoadjuvant therapy in breast cancer Primary
More informationNeoadjuvantTreatment In BC When, How, Who?
NeoadjuvantTreatment In BC When, How, Who? Clifford Hudis, M.D. Chief, Breast Cancer Medicine Service, MSKCC Professor of Medicine, Weill Cornell Medical College President, ASCO 15 Potential Benefits Of
More informationNovel Preoperative Therapies for HER2-Positive Breast Cancer. Debu Tripathy, MD University of Southern California Norris Comprehensive Cancer Center
Novel Preoperative Therapies for HER2-Positive Breast Cancer Debu Tripathy, MD University of Southern California Norris Comprehensive Cancer Center Key Findings to Date in the Neoadjuvant Therapy of HER2+
More informationMolecular alterations in triple-negative breast cancer the road to new treatment strategies
1 Molecular alterations in triple-negative breast cancer the road to new treatment strategies Carsten Denkert 1, Cornelia Liedtke 2, Andrew Tutt 3, Gunter von Minckwitz 4 Affiliations of authors: 1 Institute
More informationBreast Cancer Immunotherapy. Leisha A. Emens, MD PhD Johns Hopkins University Bloomberg Kimmel Institute for Cancer Immunotherapy
Breast Cancer Immunotherapy Leisha A. Emens, MD PhD Johns Hopkins University Bloomberg Kimmel Institute for Cancer Immunotherapy Conflict of Interest I have the following financial relationships to disclose:
More informationReview of adjuvant and neo-adjuvant abstracts from SABCS 2011 January 7 th 2012
Review of adjuvant and neo-adjuvant abstracts from SABCS 2011 January 7 th 2012 Ruth M. O Regan, MD Professor and Vice-Chair for Educational Affairs, Department of Hematology and Medical Oncology, Emory
More informationEmerging Strategies in Triple-Negative Breast Cancer
Expert Review in Immunotherapy in Breast Cancer Emerging Strategies in Triple-Negative Breast Cancer Reference Slide Deck Is Breast Cancer Immunogenic? Recent proof that breast cancer may elicit an immune
More informationLo Studio Geparsepto. Alessandra Fabi Oncologia Medica 1
Lo Studio Geparsepto Alessandra Fabi Oncologia Medica 1 nab-paclitaxel Versus Solvent-Based Paclitaxel in Neoadjuvant Chemotherapy for Early Breast Cancer (GeparSepto GBG 69): A Randomised, Phase III Trial
More informationEvolving Insights into Adjuvant Chemotherapy. Joyce O Shaughnessy, MD Baylor Sammons Cancer Center Texas Oncology US Oncology
Evolving Insights into Adjuvant Chemotherapy Joyce O Shaughnessy, MD Baylor Sammons Cancer Center Texas Oncology US Oncology 80 70 60 50 40 30 20 10 0 EBCTCG 2005/6 Overview Control Arms with No Systemic
More informationGene Signatures in Breast Cancer: Moving Beyond ER, PR, and HER2? Lisa A. Carey, M.D. University of North Carolina USA
Gene Signatures in Breast Cancer: Moving Beyond ER, PR, and HER2? Lisa A. Carey, M.D. University of North Carolina USA When Are Biomarkers Ready To Use? Same Rules for Gene Expression Panels Key elements
More information6/22/2017 TARGETING THE TARGETS IN 2017 TARGETING THE TARGETS IN 2017
TARGETING THE TARGETS IN 2017 Primary Care Focus Symposium July 1, 2017 Grace Wang MD I do not have any relevant financial relationships to disclose at this time TARGETING THE TARGETS IN 2017 What are
More information(Neo)Adjuvant Chemotherapy and biological Agents (essentials in HER2 and TN early breast cancer)
(Neo)Adjuvant Chemotherapy and biological Agents (essentials in HER2 and TN early breast cancer) Giuseppe Curigliano MD, PhD Breast Cancer Program Division of Experimental Therapeutics Outline Neoadjuvant
More informationPoint of View on Early Triple Negative
Point of View on Early Triple Negative Valentina Rossi, MD UOSD Oncologia dei Tumori della Mammella Azienda Ospedaliera S.Camillo-Forlanini VRossi@scamilloforlanini.rm.it Outline Neoadjuvant Setting IPSY-2
More informationDR LUIS MANSO UNIDAD TUMORES DE MAMA Y GINECOLÓGICOS HOSPITAL 12 DE OCTUBRE MADRID
DR LUIS MANSO UNIDAD TUMORES DE MAMA Y GINECOLÓGICOS HOSPITAL 12 DE OCTUBRE MADRID RESUMEN DE ARTICULOS THERESA BOLERO 3 NOAH UP-DATE GEPAR SIXTO RADIOTHERAPY EBCTCG CTCs MISCELANEAS Lancet Oncol 2014;
More informationAGO e. V. in der DGGG e.v. sowie in der DKG e.v.
AGO e. V. in der DGGG e.v. sowie in der DKG e.v. Guidelines Breast Version 2015.1 www.ago-online.de Disease-Free and Overall Survival in Metastatic Breast Cancer AGO e. V. in der DGGG e.v. sowie in der
More informationSystemic Treatment of Triple Negative Breast Cancer
Systemic Treatment of Triple Negative Breast Cancer Christoph Zielinski Comprehensive Cancer Center Medical University Vienna General Hospital, Vienna, Austria and Central European Cooperative Oncology
More informationBiomarkers for HER2-directed Therapies : Past Failures and Future Perspectives
Biomarkers for HER2-directed Therapies : Past Failures and Future Perspectives Ian Krop Dana-Farber Cancer Institute Harvard Medical School Inchon 2018 Adjuvant Trastuzumab Improves Outcomes in HER2+ Breast
More informationEvolving Paradigms in HER2+ MBC: Strategies for Individualizing Therapy with Available Agents
Evolving Paradigms in HER2+ MBC: Strategies for Individualizing Therapy with Available Agents Kimberly L. Blackwell MD Professor Department of Medicine and Radiation Oncology Duke University Medical Center
More informationImmunotherapy in breast cancer. Carmen Criscitiello, MD, PhD European Institute of Oncology Milan, Italy
Immunotherapy in breast cancer Carmen Criscitiello, MD, PhD European Institute of Oncology Milan, Italy Outline Rational for immune-based therapy in breast cancer Immunogenic chemotherapy Targeting immune
More informationNivolumab: esperienze italiane nel carcinoma polmonare avanzato
NSCLC avanzato: quali novità nel 2018? Negrar, 30 Ottobre 2018 Nivolumab: esperienze italiane nel carcinoma polmonare avanzato Francesco Grossi UOC Oncologia Medica Fondazione IRCCS Ca Granda Ospedale
More information4, :00 PM 9:00 PM
Consensus or Controversy? Clinical Investigators Provide Their Perspectives on Practical Issues and Research Questions in the Management of Breast Cancer Robert W Carlson, MD John Crown, MD Charles E Geyer
More informationTriple Negative Breast Cancer
GASCO 2016 San Antonio Breast Cancer Symposium Review Triple Negative Breast Cancer Amelia Zelnak, MD, MSc Atlanta Cancer Care Northside Hospital Cancer Institute Disclosures: consultant for Novartis,
More informationImmune Checkpoint Inhibitors for Lung Cancer William N. William Jr.
Immune Checkpoint Inhibitors for Lung Cancer William N. William Jr. Diretor de Onco-Hematologia Hospital BP, A Beneficência Portuguesa Non-Small Cell Lung Cancer PD-1/PD-L1 Inhibitors in second-line therapy
More informationNeo-adjuvant and adjuvant treatment for HER-2+ breast cancer
Neo-adjuvant and adjuvant treatment for HER-2+ breast cancer Angelo Di Leo «Sandro Pitigliani» Medical Oncology Unit Hospital of Prato Istituto Toscano Tumori Prato, Italy NOAH: Phase III, Open-Label Trial
More informationPARP inhibitors for breast cancer
PARP inhibitors for breast cancer Mark Robson, MD Memorial Sloan Kettering Cancer Center Agenda Mechanism of action Clinical studies Resistance mechanisms Future directions Poly (ADP-ribose) Polymerases
More informationPerspectivas de desarrollo de la inmunoterapia en cáncer de mama hereditario. Luis de la Cruz Merino Oncología Médica HUVMacarena (Sevilla)
Perspectivas de desarrollo de la inmunoterapia en cáncer de mama hereditario Luis de la Cruz Merino Oncología Médica HUVMacarena (Sevilla) Outline Immunology and breast cancer Clinical trials with modern
More informationSan Antonio Breast Cancer Symposium, December 5-9, San Antonio Breast Cancer Symposium, December 5-9, 2017
San Antonio Breast Cancer Symposium, December 5-9, 2017 Survival analysis of the prospectively randomized phase III GeparSepto trial comparing neoadjuvant chemotherapy with weekly nab-paclitaxel with solvent-based
More informationDieta Brandsma, Department of Neuro-oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands
What is hot in breast cancer brain metastases? Dieta Brandsma, Department of Neuro-oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands 8th Annual Brain Metastases Research and Emerging Therapy
More informationHER2-Targeted Rx. An Historical Perspective
HER2-Targeted Rx An Historical Perspective Trastuzumab: Front Line Rx for MBC Median 20.3 v. 25.1 mo P = 0.046 HR 0.8 65% of control patients crossed over Slamon D, et al. N Engl J Med, 2001; 344:783 Trastuzumab:Front-line
More informationCáncer de mama HER2+/RE+ vs HER2+/RE : Una misma enfermedad? Dra E. Ciruelos Departamento de Oncología Médica Hospital Universitario 12 de Octubre
Cáncer de mama HER2+/RE+ vs HER2+/RE : Una misma enfermedad? Dra E. Ciruelos Departamento de Oncología Médica Hospital Universitario 12 de Octubre Recurrence of HER2-positive breast cancer (A) Time to
More informationUpdate on Breast Cancer
Update on Breast Cancer William J. Gradishar, MD Professor of Medicine Robert H. Lurie Comprehensive Cancer Center Feinberg School of Medicine Northwestern University Overview PARP Inhibitors Neoadjuvant
More informationChemotherapy With or Without Targeted Drugs* in Metastatic Breast Cancer
Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer Chemotherapy With or Without Targeted Drugs* in Metastatic Breast Cancer * Substances without published evidence based on at
More informationUpdates in Immunotherapy for Urothelial Carcinoma
Updates in Immunotherapy for Urothelial Carcinoma Andrew J Armstrong MD ScM FACP DUA 2018 Copyright 2006 SciMed. Talk Outline Immunotherapy progress in 2017: 5 new approved PD-1/PD-L1 inhibitory agents
More informationEdith A. Perez, Ahmad Awada, Joyce O Shaughnessy, Hope Rugo, Chris Twelves, Seock-Ah Im, Carol Zhao, Ute Hoch, Alison L. Hannah, Javier Cortes
BEACON: A Phase 3 Open-label, Randomized, Multicenter Study of Etirinotecan Pegol (EP) versus Treatment of Physician s Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously
More informationMalattia HER-2 positiva
Novità sul trattamento del carcinoma mammario Malattia HER-2 positiva Patrizia Vici Neoadjuvant - Adjuvant - Advanced Prognostic/Predictive factors..her-2 heterogeneity.. Neoadjuvant Phase II Pre-planned
More informationLecture 5. Primary systemic therapy: clinical and biological endpoints
Lecture 5 Primary systemic therapy: clinical and biological endpoints Valentina Guarneri, M.D., Ph.D. Primary systemic therapy in breast cancer Firstly introduced d into clinical i l practice in 70s for
More informationSystemic therapy: HER-2 update. Hans Wildiers Multidisciplinair Borst Centrum/Algemene medische oncologie UZ Leuven
Systemic therapy: HER-2 update Hans Wildiers Multidisciplinair Borst Centrum/Algemene medische oncologie UZ Leuven New drugs Strategic issues Specific anti-her2 drugs Lapa$nib /Nera$nib Baselga & Swain,
More informationOptions for first-line cisplatin-eligible patients
The Past Options for first-line cisplatin-eligible patients Metastatic urothelial cancer Cisplatin-eligible Gemcitabine/ cisplatin MVAC or high-dose intensity MVAC Paclitaxel/ cisplatin/ gemcitabine Bellmunt
More informationExpert Review: The Role of PARP Inhibition in the Treatment of Breast Cancer. Reference Slides
Expert Review: The Role of PARP Inhibition in the Treatment of Breast Cancer Reference Slides Overview BRCA Mutations and Breast Cancer Patients with BRCA mutations have an estimated 55% to 65% cumulative
More informationDisease Update: Metastatic Breast Cancer
Disease Update: Metastatic Breast Cancer Aimee Faso, PharmD, BCOP, CPP Oncology Clinical Specialist, GI/Breast UNC Hospitals and Clinics August 2015 Objectives Identify treatment choices of metastatic
More informationConversations in Oncology. November Kerry Hotel Pudong, Shanghai China
Conversations in Oncology November 12-13 Kerry Hotel Pudong, Shanghai China Immunotherapy of Lung Cancer Professor Caicun Zhou All materials are for scientific exchanges. Afatinib and nintedanib are not
More informationESMO Preceptoship in Immuno-Oncology. Clinical Development: Breast Cancer
ESMO Preceptoship in Immuno-Oncology Clinical Development: Breast Cancer Prof Giuseppe Curigliano, MD PhD University of Milano and Istituto Europeo di Oncologia Milano, Lombardia, Italy Outline Rational
More informationTargeted Agents as Maintenance Therapy. Karen Kelly, MD Professor of Medicine UC Davis Cancer Center
Targeted Agents as Maintenance Therapy Karen Kelly, MD Professor of Medicine UC Davis Cancer Center Disclosures Genentech Advisory Board Maintenance Therapy Defined Treatment Non-Progressing Patients Drug
More informationNew chemotherapy drugs in metastatic breast cancer. Guy Jerusalem, MD, PhD
New chemotherapy drugs in metastatic breast cancer Guy Jerusalem, MD, PhD MBC Patients survival over time Median survival increases over time, but is still measured in months This is not yet a chronic
More informationA case of a BRCA2-mutated ER+/HER2 breast cancer during pregnancy
ESMO Preceptorship Programme Breast Cancer Lisbon 16,17 September 2016 Emanuela Risi Sandro Pitigliani Medical Oncology Department Hospital of Prato, Istituto Toscano Tumori, Prato, Italy A case of a BRCA2-mutated
More informationBreast Cancer: ASCO Poster Review
Breast Cancer: ASCO Poster Review Carmen Criscitiello, MD, PhD Istituto Europeo di Oncologia Milano HER2+ SUBTYPE Research questions in early HER2+ BC De-escalation of toxicity without compromising efficacy
More informationUpdate on the Management of HER2+ Breast Cancer. Christian Jackisch, MD, PhD Sana Klinikum Offenbach Offenbach, Germany
Update on the Management of HER2+ Breast Cancer Christian Jackisch, MD, PhD Sana Klinikum Offenbach Offenbach, Germany Outline Treatment strategies for HER2-positive metastatic breast cancer since First
More informationCOME HOME Innovative Oncology Business Solutions, Inc.
Innovative Oncology Business Solutions, Inc. Breast Cancer Diagnostic/Therapeutic Pathway V11, April 2015 Required Structured Data Fields: ICD9 Code Stage Staging Components Performance Status Treatment
More informationHER2-positive Breast Cancer
HER2-positive Breast Cancer Multiple choices what to use when? Thomas Ruhstaller Brustzentrum St. Gallen Adjuvant setting NCIC MA5 N Engl J Med 06, 2103 6 x CEF can 6 x CMF oral HER2 + pg schlecht in allen
More informationNSCLC: immunotherapy as a first-line treatment. Paolo Bironzo Oncologia Polmonare AOU S. Luigi Gonzaga Orbassano (To)
NSCLC: immunotherapy as a first-line treatment Paolo Bironzo Oncologia Polmonare AOU S. Luigi Gonzaga Orbassano (To) The 800-pound gorilla Platinum-based chemotherapy is the SOC for 1st-line therapy in
More informationProstate cancer Management of metastatic castration sensitive cancer
18 th Annual Advances in Oncology - 2017 Prostate cancer Management of metastatic castration sensitive cancer Urothelial carcinoma Non-muscle invasive urothelial carcinoma Updates in metastatic urothelial
More informationSystemic Therapy Considerations in Inflammatory Breast Cancer
Systemic Therapy Considerations in Inflammatory Breast Cancer Shani Paluch-Shimon, MBBS, MSc Director, Breast Oncology Unit Shaare Zedek Medical Centre, Jerusalem Israel Disclosures Roche: Speakers bureau,
More information14,30 18,20. II Sessione. Moderatori: Giovanni Apolone, Roberto Labianca
14,30 18,20 II Sessione Moderatori: Giovanni Apolone, Roberto Labianca 14,30 14,50 Ca mammario: attualità e prospettive di ricerca Luca Livraghi Carcinoma mammario: attualità e prospettive di ricerca LUCA
More informationThe Role of Pathologic Complete Response (pcr) as a Surrogate Marker for Outcomes in Breast Cancer: Where Are We Now?
1 The Role of Pathologic Complete Response (pcr) as a Surrogate Marker for Outcomes in Breast Cancer: Where Are We Now? Terry Mamounas, M.D., M.P.H., F.A.C.S. Medical Director, Comprehensive Breast Program
More informationPositive HER-2 tumor. How to incorporate the new drugs into neoadjuvance
Oncology Department Vall d Hebron University Hospital Barcelona. Spain Positive HER-2 tumor. How to incorporate the new drugs into neoadjuvance Javier Cortés June/2013 MD Anderson experience Buzdar et
More informationA view from the Oncology Clinic. Andrew Tu7 Consultant Clinical Oncologist
A view from the Oncology Clinic Andrew Tu7 Consultant Clinical Oncologist Our pa'ents have become much more aware and are driving a changing demand Before surgery: MRI for contralateral BC; neoadjuvant
More informationOverview and future horizons of PARP inhibitors in BRCAassociated. Judith Balmaña
Overview and future horizons of PARP inhibitors in BRCAassociated breast cancer Judith Balmaña PARP inhibitors: Mechanism of action Clinical development: Monotherapy In combination with chemotherapy Ongoing
More informationEarly Stage Disease. Hope S. Rugo, MD Professor of Medicine Director Breast Oncology and Clinical Trials Education UCSF Comprehensive Cancer Center
SABCS 2014: Early Stage Disease Hope S. Rugo, MD Professor of Medicine Director Breast Oncology and Clinical Trials Education UCSF Comprehensive Cancer Center Topics for Discussion Chemotherapy plus 10
More informationExpanding Therapeutic Strategies for HER2-Positive Metastatic Breast Cancer
Expanding Therapeutic Strategies for HER2-Positive Metastatic Breast Cancer Sara A. Hurvitz, MD, FACP Associate Professor of Medicine University of California Los Angeles Los Angeles, California Trastuzumab
More informationMETRIC Study Key Eligibility Criteria
The METRIC Study METRIC Study Key Eligibility Criteria The pivotal METRIC Study is evaluating glembatumumab vedotin in patients with gpnmb overexpressing metastatic triple-negative breast cancer (TNBC).
More informationPost-ASCO 2017 Cancer du sein Triple Négatif
Post-ASCO 217 Cancer du sein Triple Négatif A.Ladjeroud, K.Bouzid Centre Pierre et Marie Curie- Alger Oran, 3 Septembre 217 Phase III Investigation of Neoadjuvant Carboplatin ± Veliparib in Combination
More informationThe Rationale for Immunotherapy as an Adjuvant Treatment for Locally Advanced BC
The Rationale for Immunotherapy as an Adjuvant Treatment for Locally Advanced BC Seth P. Lerner, MD, FACS Professor, Scott Department of Urology Beth and Dave Swalm Chair in Urologic Oncology Baylor College
More informationUrothelial Cancers- New Strategies. Sandy Srinivas.MD Stanford University
Urothelial Cancers- New Strategies Sandy Srinivas.MD Stanford University Relevant financial relationships in the past twelve months by presenter or spouse/partner. Consultant: Genentech, Astra Zeneca The
More informationAny News in EBC? Ann H. Partridge, MD, MPH Dana-Farber Cancer Institute November 11, 2016
Any News in EBC? Ann H. Partridge, MD, MPH Dana-Farber Cancer Institute November 11, 2016 Yes! Age disparities vary by tumor subtype Genomic risk prediction data in young women Adjuvant systemic therapy
More informationNovel Chemotherapy Agents for Metastatic Breast Cancer. Joanne L. Blum, MD, PhD Baylor-Sammons Cancer Center Dallas, TX
Novel Chemotherapy Agents for Metastatic Breast Cancer Joanne L. Blum, MD, PhD Baylor-Sammons Cancer Center Dallas, TX New Chemotherapy Agents in Breast Cancer New classes of drugs Epothilones Halichondrin
More informationEvolving Insights into Adjuvant Chemotherapy. Joyce O Shaughnessy, MD Baylor Sammons Cancer Center Texas Oncology US Oncology
Evolving Insights into Adjuvant Chemotherapy Joyce O Shaughnessy, MD Baylor Sammons Cancer Center Texas Oncology US Oncology Dilemmas in Adjuvant Chemotherapy Is adjuvant chemotherapy effective in ER+
More information